Research statistics
CJC-1295 (no DAC) / Mod GRF(1-29) research: publications and trials
At a glance
Publications, all years
1
Since 2026
Publications in 2026 so far
1
Through November 15, 2026
Human clinical research
0.0%
0 of 1 classified
Registered clinical trials
0
ClinicalTrials.gov
Randomized controlled trials
0
Publications reporting an RCT in people
Systematic reviews and meta-analyses
0
Preclinical studies
0.0%
0 animal · 0 in vitro · 0 computational
Records that only mention it
0
Not counted above
Status in the library: Research only. Groups: Growth hormone axis.
What to keep in mind
- No human clinical publication is indexed: everything published so far is preclinical, a review or commentary.
- Fewer than three randomized controlled trials are indexed.
- Fewer than 25 publications are indexed, so year-to-year changes are not meaningful.
Publications by year
CJC-1295 (no DAC) / Mod GRF(1-29) publications by year and evidence
Show the data
| Year | Reviews and meta-analyses |
|---|---|
| 2026 (to date) | 1 |
Study types
| Review | 1 |
|---|
Research areas
From MeSH major topics. A paper can be in several areas.
| Endocrinology | 1 |
|---|---|
| Metabolic health | 1 |
| Musculoskeletal | 1 |
| Obesity and weight management | 1 |
Registered clinical trials
A registration is not a result.
No registered trials.
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
No human trial, systematic review or meta-analysis of CJC-1295 (no DAC) / Mod GRF(1-29) is indexed.
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
Frontiers in endocrinology · June 18, 2026 · Review · cited 1 times · open access
PMID 42395176 · DOI 10.3389/fendo.2026.1822475 · Reviews and meta-analyses
Latest publications
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
Frontiers in endocrinology · June 18, 2026 · Review · cited 1 times · open access
PMID 42395176 · DOI 10.3389/fendo.2026.1822475 · Reviews and meta-analyses
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: CJC-1295 without DAC; CJC no DAC; Mod GRF; Mod GRF(1-29); ModGRF; Tetrasubstituted GRF
((TITLE_ABS:"CJC-1295 without DAC" OR CHEM:"CJC-1295 without DAC" OR TITLE_ABS:"CJC1295 without DAC" OR CHEM:"CJC1295 without DAC") OR (TITLE_ABS:"CJC no DAC" OR CHEM:"CJC no DAC") OR (TITLE_ABS:"Mod GRF" OR CHEM:"Mod GRF") OR (TITLE_ABS:"Mod GRF(1-29)" OR CHEM:"Mod GRF(1-29)") OR (TITLE_ABS:"ModGRF" OR CHEM:"ModGRF") OR (TITLE_ABS:"Tetrasubstituted GRF" OR CHEM:"Tetrasubstituted GRF")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 16). CJC-1295 (no DAC) / Mod GRF(1-29) research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/cjc-1295-no-dac